- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.02. | OncoZenge AB: OncoZenge AB Year-end Report January 1 - December 31, 2025 | 90 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced its full year report for 2025, a year of significant progress culminating in the submission of the Phase III Clinical Trial Application... ► Artikel lesen | |
| 12.02. | OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical | 210 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the third tranche of investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor").
The investment... ► Artikel lesen | |
| 02.02. | OncoZenge AB: OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer | 244 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company"), a clinical-stage pharmaceutical company developing innovative treatments for oral pain, today announced the appointment of Dr. Marie-Louise Fjällskog, MD, PhD, as... ► Artikel lesen | |
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 30.01. | OncoZenge AB: OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge Technology Batch, Advancing Toward Clinical Trials | 135 | GlobeNewswire (Europe) | OncoZenge AB (publ), a pharmaceutical company developing innovative treatments for oral pain management, today announced that the one-month stability study results for its BupiZenge lozenge technology... ► Artikel lesen | |
| 22.01. | OncoZenge AB: OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds | 458 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has today entered into an agreement for a bridge financing solution of SEK 5 million, via a convertible note with Linc AB ("Linc") to be repaid upon... ► Artikel lesen | |
| 22.01. | OncoZenge AB receives observation status | 166 | GlobeNewswire | Yesterday, January 21, 2026, OncoZenge AB (the "Company") disclosed a press release with information about uncertainties regarding the payment of the subscription proceeds in a previously announced... ► Artikel lesen | |
| 21.01. | OncoZenge AB: OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact | 252 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company") has just been informed that the strategic investor Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (the "Investor") will not be able to pay the subscription proceeds... ► Artikel lesen | |
| 19.12.25 | OncoZenge AB: OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement | 167 | GlobeNewswire (Europe) | The information contained in this press release is not for publication, release or distribution, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand... ► Artikel lesen | |
| 03.12.25 | OncoZenge AB: OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge for Europe | 131 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company"), a pharmaceutical company developing BupiZenge, an innovative non-opioid therapy for treating oral pain, today announces an amended agreement with... ► Artikel lesen | |
| 17.11.25 | OncoZenge AB: OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge | 186 | GlobeNewswire (Europe) | OncoZenge AB (publ) (Nasdaq First North Growth Market: ONCOZ), a pharmaceutical company developing BupiZenge, an innovative non-opioid therapy for treating oral pain, today announces the addition of... ► Artikel lesen | |
| 30.10.25 | OncoZenge AB: OncoZenge AB Interim Report January 1 - September 30, 2025 | 368 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the third quarter of 2025. The Company reports receipt of investment funds for its European Phase III program... ► Artikel lesen | |
| 09.10.25 | OncoZenge AB: OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study | 146 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a pharmaceutical company developing an innovative treatment for oral pain relief, today announced that University of California, Los Angeles (UCLA)... ► Artikel lesen | |
| 17.09.25 | OncoZenge AB: OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge | 174 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a pharmaceutical company developing an innovative treatment for oral pain relief, today announced a new collaboration with the University of California... ► Artikel lesen | |
| 10.09.25 | OncoZenge AB: OncoZenge AB appoints LINK Medical as CRO for BupiZenge Phase III execution | 527 | GlobeNewswire (Europe) | OncoZenge AB has selected LINK Medical, a Nordic-based clinical research organization (CRO), to lead the Phase III trial for BupiZenge, its innovative drug candidate designed to relieve oral pain from... ► Artikel lesen | |
| 21.08.25 | OncoZenge AB: OncoZenge AB Interim Report January 1 - June 30, 2025 | 257 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2025. The Company's Phase III program has moved into execution. Preparations are now underway... ► Artikel lesen | |
| 30.07.25 | OncoZenge AB: OncoZenge Provides Market and Strategy Update | 476 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced a comprehensive market and strategy update after successfully securing full funding for its BupiZenge Phase 3 clinical trial aimed... ► Artikel lesen | |
| 21.07.25 | OncoZenge AB: OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge Phase 3 Project | 187 | GlobeNewswire (Europe) | OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions ("Meribel," formerly Recipharm) as its Contract Development and Manufacturing Organization (CDMO)... ► Artikel lesen | |
| 17.07.25 | OncoZenge AB: OncoZenge and Molteni Farmaceutici Sign Amendment to Focus BupiZenge Phase 3 Project in Europe | 244 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the signing of an amendment to the license and supply agreement with Molteni Farmaceutici. This amendment accelerates certain milestones... ► Artikel lesen | |
| 11.07.25 | OncoZenge AB: OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical | 176 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the initial investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the "Investor").
On January 27, 2025... ► Artikel lesen | |
| 08.07.25 | OncoZenge AB: OncoZenge Appoints Tuulikki Lindmark as Head of CMC in Phase 3 Sponsor Team | 309 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") announces today that the sponsor team for the phase 3 project with BupiZenge is strengthened by the addition of Tuulikki Lindmark, who joins the Company... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 31,920 | -0,08 % | Eli Lilly und Novo Nordisk: Aktien nach Watsche von Analysten tief im Minus | Ein überraschender Kursrutsch erschüttert den Pharmariesen Eli Lilly, nachdem HSBC die Aktie auf "Reduce" herabgestuft hat. Die Analysten sehen das Kursniveau als zu ambitioniert und zweifeln an den... ► Artikel lesen | |
| ASTRAZENECA | 162,40 | +1,25 % | Hacker stehlen AstraZeneca-Quellcode | ||
| CAMURUS | 41,680 | +1,86 % | Camurus AB: Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer | Lund, Sweden - 17 February 2026 - Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus' Chief Corporate Development Officer (CCDO) and member of the executive... ► Artikel lesen | |
| BAYER | 38,265 | +1,39 % | Hensoldt Aktie: Zurück zum Hoch? - Bayer, Energiekontor, MuM, Mutares und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MERCK KGAA | 106,00 | +2,56 % | EQS-DD: Merck KGaA: Belén Garijo Lopez, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.03.2026 / 10:59... ► Artikel lesen | |
| GSK | 23,540 | +3,20 % | FDA genehmigt Lynavoy von GSK zur Behandlung von Juckreiz bei PBC | Der britische Pharmakonzern GSK plc hat die Zulassung seines Medikaments Lynavoy in den USA erhalten. Die US-Arzneimittelbehörde U.S. Food and Drug Administration genehmigte das Präparat zur Behandlung... ► Artikel lesen | |
| PFIZER | 23,365 | +0,37 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen | |
| DERMAPHARM | 42,600 | +1,91 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| SANOFI | 79,28 | +1,78 % | BERENBERG stuft SANOFI auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Sanofi mit einem Kursziel von 105 Euro auf "Buy" belassen. Die Zurückhaltung der Anleger vor der Strategievorstellung des neuen Chefs bremse... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 22,970 | 0,00 % | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS... ► Artikel lesen | |
| GRIFOLS | 9,006 | +2,46 % | Grifols approves IPO of its US biopharma business | ||
| PMGC | 2,880 | 0,00 % | Morning Market Movers: PMGC Holdings, urban-gro, PTL Limited, Ridgetech See Big Swings | BEIJING (dpa-AFX) - At 8:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,610 | 0,00 % | Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension | Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase... ► Artikel lesen | |
| HARROW | 35,180 | 0,00 % | Harrow prices $50 million debt offering at 8.625% due 2030 | ||
| SCHOTT PHARMA | 13,440 | +1,05 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Schott Pharma von 19 auf 16 Euro gesenkt, aber die Einstufung auf "Hold" belassen. Die Ergebnisse des ersten Geschäftsquartals... ► Artikel lesen |
Das Unternehmen ONCOZENGE AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,97 % bei einem Aktienkurs von 0,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.